Articles related to Surgery, Plastic

You want speedy access to comprehensive records. Clinical decision-making tools. Optimized communication and data exchange. EHRs should be as unique as you, so whether you’re looking to replace or implement your first, this list can get you started.

Although the 2020 numbers will likely look MUCH different, the Merritt Hawkins survey from 2019 showed increased gains from previous years. Of the 62 responses representing 93 hospitals, cardiovascular surgery drove the most revenue. Still, the outlook remains bleak post-pandemic.

Trilaciclib (Cosela, G1 Therapeutics), a cyclin dependent kinase 4/6 inhibitor, is already approved in the United States to reduce frequency of chemotherapy-related bone marrow suppression among adults with extensive-stage small cell lung cancer. Now, the FDA has granted fast track designation to the drug for use in combo with chemo for treatment of locally advanced or metastatic TNBC.

According to a study of 135,000 doctors by Doximity, male physicians made, on average, 28% more than females in 2020, a 3% increase from the 2019 numbers. The survey, along with Medscape’s poll in 2021 that showed male specialist physicians overall making 33% more than females, points to a few other large gender pay gaps, as well as some in which women doctors make salaries closer to those of men.

There are several reasons why the COVID-19 Delta variant – responsible for the COVID crisis in India – has public health experts and doctors concerned, including its transmissibility and disease severity. You likely already know the Delta “variant of concern” is more contagious than previous variants (denoted by the Greek alphabet), but here are five other important details you should be aware of.

This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated in the Stockholm tamoxifen (STO-3) trial from 1976 to 1990.